TITLE
Imatinib mesylate effect on bone marrow hematopoietic cells of chronic myeloid leukemia patients

SUMMARY
Analysis of bone marrow hematopoietic cells in chronic myeloid leukemia (CML) patients one month after imatinib mesylate (IM) therapy. CML is caused by expression of the BCR/ABL fusion oncogene. Results provide insight into the molecular consequences of IM blockade of oncoprotein Bcr-Abl in CML.

ORGANISM
Homo sapiens

PLATFORM
GPL570 : [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array

CITATIONS
Benito R, Lumbreras E, Abáigar M, Gutiérrez NC et al. Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progression. Pharmacogenet Genomics 2012 May;22(5):381-8. PMID:  22388797

